Share count
94Mpeak FY2025
← All companies ← CEPU Manual CGNT → ← CCCC Biotechnology CGON →
CGEN, Compugen Ltd.
We are a clinical-stage therapeutic discovery and development company utilizing Unigen , our AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapy.
Currently, the only clinical trial we sponsor and are conducting is a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial) and we expect an interim analysis from this trial in the first quarter of 2027.
The business
What it sells, where the money comes from, the kind of company it is.
Revenue · FY2025
$73M
+161.1% YoY · 105% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $73M 5-yr avg $30M
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
- What moves the needle
- Operating margin has reached 43% at its best but run negative through the cycle (median −472%) on a 87% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −30%, above 15% in 1 of 8 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2018’18 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMDec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| $712K | $18M | $2M | $6M | $8M | $33M | $28M | $73M | $73M | RevenueRevenue |
| 69% | 94% | 97% | 89% | 87% | 94% | 72% | 87% | 87% | Gross marginGross mgn |
| ($33M) | ($23M) | ($31M) | ($35M) | ($35M) | ($13M) | ($15M) | $31M | $31M | Operating incomeOp. inc. |
| n/m | −130.5% | n/m | −584.6% | −471.7% | −38.8% | −53.4% | 43.1% | 43.1% | Operating marginOp. mgn |
| ($32M) | ($23M) | ($30M) | ($34M) | ($34M) | ($19M) | ($14M) | $35M | $35M | Net incomeNet inc. |
| Cash flow & returns | |||||||||
| ($20M) | ($13M) | ($28M) | ($23M) | ($34M) | ($36M) | $50M | $32M | $32M | Operating cash flowOp. cash |
| $1M | $1M | $715K | $461K | $482K | $476K | $486K | $475K | $475K | DepreciationDeprec. |
| $10M | $8M | $663K | $11M | ($901K) | ($18M) | $63M | ($4M) | ($4M) | Working capital & otherWC & other |
| $3M | $158K | $166K | $292K | $477K | $172K | $118K | $306K | $306K | CapexCapex |
| 365.0% | 0.9% | 8.3% | 4.9% | 6.4% | 0.5% | 0.4% | 0.4% | 0.4% | Capex / revenueCapex/rev |
| ($21M) | ($13M) | ($28M) | ($23M) | ($35M) | ($36M) | $49M | $31M | $31M | Owner earningsOwner earn. |
| n/m | −75.6% | n/m | −383.0% | −461.2% | −107.8% | 177.6% | 43.1% | 43.1% | Owner earnings marginOE mgn |
| ($22M) | ($13M) | ($28M) | ($23M) | ($35M) | ($36M) | $49M | $31M | $31M | Free cash flowFCF |
| n/m | −75.6% | n/m | −383.0% | −461.2% | −107.8% | 177.6% | 43.1% | 43.1% | Free cash flow marginFCF mgn |
| -48% | -58% | -22% | -28% | -42% | -20% | -32% | 258% | 258% | ROICROIC |
| -50% | -61% | -25% | -32% | -43% | -29% | -26% | 34% | 34% | Return on equityROE |
| −50% | −61% | −25% | −32% | −43% | −29% | −26% | 34% | 34% | Retained to equityRetained/eq |
| Balance sheet | |||||||||
| $10M | $6M | $7M | $8M | $11M | $26M | $42M | $100M | $100M | Cash & investmentsCash+inv |
| $400K | — | $2M | — | $0 | $61M | $5M | — | $5M | ReceivablesReceiv. |
| $1M | $3M | $1M | $5M | $2M | $4M | $2M | $2M | $2M | Accounts payablePayables |
| ($874K) | — | $587K | — | ($2M) | $57M | $3M | — | $3M | Operating working capitalOper. WC |
| $63M | $47M | $129M | $123M | $86M | $115M | $106M | $148M | $148M | Current assetsCur. assets |
| $5M | $10M | $11M | $17M | $12M | $26M | $20M | $23M | $23M | Current liabilitiesCur. liab. |
| 13.2× | 4.7× | 12.3× | 7.2× | 7.2× | 4.4× | 5.3× | 6.6× | 6.6× | Current ratioCurr. ratio |
| $71M | $53M | $138M | $132M | $94M | $121M | $115M | $157M | $157M | Total assetsAssets |
| ($10M) | ($6M) | ($7M) | ($8M) | ($11M) | ($26M) | ($42M) | ($100M) | ($100M) | Net debt / (cash)Net debt |
| -1416.7× | -1009.9× | -749.9× | -1403.0× | -1310.1× | -419.1× | -438.0× | 1118.8× | 1118.8× | Interest coverageInt. cov. |
| $64M | $37M | $120M | $107M | $78M | $66M | $55M | $103M | $103M | Shareholders’ equityEquity |
| Per share | |||||||||
| 50.9M | 55.3M | 79.6M | 84.2M | 86.6M | 87.6M | 89.5M | 93.8M | 94.6M | Shares out (diluted)Shares |
| $0.01 | $0.32 | $0.03 | $0.07 | $0.09 | $0.38 | $0.31 | $0.78 | $0.77 | Revenue / shareRev/sh |
| $-0.62 | $-0.41 | $-0.37 | $-0.41 | $-0.39 | $-0.21 | $-0.16 | $0.38 | $0.37 | EPS (diluted)EPS |
| $-0.42 | $-0.24 | $-0.36 | $-0.27 | $-0.40 | $-0.41 | $0.55 | $0.33 | $0.33 | Owner earnings / shareOE/sh |
| $-0.44 | $-0.24 | $-0.36 | $-0.27 | $-0.40 | $-0.41 | $0.55 | $0.33 | $0.33 | Free cash flow / shareFCF/sh |
| $0.05 | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | Cap. spending / shareCapex/sh |
| $1.25 | $0.67 | $1.50 | $1.27 | $0.90 | $0.75 | $0.61 | $1.10 | $1.09 | Book value / shareBVPS |
The diluted share count moved ×1.44 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
Per-share growththe realized rate an owner's share compounded
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +56.2%/yr | +98.6%/yr |
| Capital spending / share | −26.3%/yr | +9.4%/yr |
| Book value / share | −1.5%/yr | −6.2%/yr |
The record, charted
FY2016–2025Each measure over its full record; the current point and the worst year marked.
ROIC
258%low FY2017
Gross margin
87%low FY2016
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
$31Mowner earningsvs.$35Mnet incomelow FY2023
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business reported $35M of profit but $31M of owner earnings: $4M less than the profit line, taken out by capital spending and the timing of cash.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $35M | ($14M) | ($19M) | ($34M) | ($34M) |
| Depreciation & amortizationnon-cash charge added back | +$475K | +$486K | +$476K | +$482K | +$461K |
| Working capital & othertiming of cash in and out, other non-cash items | −$4M | +$63M | −$18M | −$901K | +$11M |
| Cash from operations | $32M | $50M | ($36M) | ($34M) | ($23M) |
| Capital expenditurecash put back in to keep running and to grow | −$306K | −$118K | −$172K | −$477K | −$292K |
| Owner earnings | $31M | $49M | ($36M) | ($35M) | ($23M) |
| Owner-earnings marginowner earnings ÷ revenue | 43% | 178% | -108% | -461% | -383% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
FY2025 20-F · source on SEC EDGAR →
Will it survive?
- Can it pay its interest? 1118.8×ComfortableOperating income $31M ÷ interest expense $28K
What this means
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- Net cash, debt-freeCash $91M + ST investments $9M − debt $0
What this means
Cash and short-term investments exceed every dollar of debt by $100M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Not enough dataIndustry peers: median -49%
What this means
The filing data didn't include the inputs for this check.
- Positive this year, negative across the cyclelatest $31M = operating cash $32M − maintenance capex $306K (positive this year), after an earlier loss stretch (8-yr median -383%)Industry peers: median -392%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 43% of revenue this year, a -383% median across 8 years.
- Mostly cash-backedCash from ops $32M ÷ net income $35M
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.64×HarvestingCapex $306K ÷ depreciation $475K
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 1 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $73M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 6.56×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Earnings stability MissA profit every year (10-yr record) · 9 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · none paid
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $0.01/share (latest year $0.37), the averaged base the calculator's gate runs on, and book value is $1.09/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 1 of 8
What this means
Lost money in 7 year(s), look at what happened there before trusting the average.
- Operating margin −2094% → −16% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about −2094% early to −16% lately, median −472% — pricing power intact or improving.
- Worst year 2016 · −4576.3% op. margin
What this means
Operations went underwater in 2016, understand why before trusting the good years.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
In its own filing Named as a competitive risk
Its FY2025 10-K names artificial intelligence as a competitive threat.
“We also face competition from companies that utilize AI/ML for target discovery in the field of immuno-oncology/cancer, some of which besides utilizing a computational platform for target discovery, also perform the molecule discovery.”
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Dec 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
Current assets$148M
- Cash & short-term investments$100M
- Receivables$5M
- Other current assets$43M
Current liabilities$23M
- Accounts payable$2M
- Other current liabilities$20M
Current ratio6.56×all current assets ÷ what's due · Graham looked for 2×
Quick ratio—inventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio4.43×strictest: cash alone against what's due
Working capital$125Mthe cushion left after near-term bills
Deeper floors
Tangible book value$103Mequity stripped of goodwill & intangibles
Debt incl. operating leases$521K$521K of it operating leases
Deferred revenue$11Mcustomer cash collected before delivery; operating float
From the company's latest filing.
Peers, Biotechnology
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| IPSCCentury Therapeutics Inc. | $109M | — | -2335.3% | -65% | -885% |
| STROSutro Biopharma Inc. | $102M | — | -142.2% | -49% | -29% |
| FDMT4D Molecular Therapeutics Inc. | $85M | — | -544.6% | -41% | -392% |
| MGTXMeiraGTx Holdings plc | $81M | — | -438.4% | -134% | -329% |
| RXRXRecursion Pharmaceuticals Inc. | $75M | 5% | -867.9% | -106% | -672% |
| CGENCompugen Ltd. | $73M | 88% | -301.1% | -37% | -245% |
| VIRVir Biotechnology Inc. | $69M | 99% | -791.3% | -45% | -611% |
| PLXProtalix BioTherapeutics Inc. (DE) | $53M | 58% | -23.5% | -1% | -33% |
| Group median | — | 73% | -491.5% | -47% | -360% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the US price, in dollars: the NYSE/Nasdaq quote you hold. Compugen Ltd.'s US listing is the ordinary share itself. The record tables elsewhere on this page remain as filed.
Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Compugen Ltd. has delivered.
$
Base
—
The assumptions
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Implied by the price—
Owner-earnings growth · since FY2024−37%/yr
Owner-earnings growth · since FY2024−37%/yr
Owner-earnings yield—
What a growth belief costs, in multiples
The growth each return requires, at your price
P/E (3-yr earnings ’23–’25)—
P/B—
Graham’s price gate—
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Against a high-grade bond: Graham’s yardstick bond yield%
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner-earnings yield—
High-grade bond yield—
Margin over the bond—
Owner earnings $31M on 95M shares outstanding, per the 20-F cover, as of 2025-12-31; net cash $100M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Cite: Owner Scorecard, "Compugen Ltd. (CGEN), the owner's record," https://ownerscorecard.com/c/CGEN, data as of 2026-07-09.
Manual order: ← CEPU its page in the Manual CGNT →
Industry order: ← CCCC the Biotechnology chapter CGON →